Corroboration Development and Regulatory approval of Fibrin Sealant
Abstract
Objective
Finding the relation between scientific evidence development and regulatory approval of medical devices in existing markets, USA (United states of America) and EU (European Union)
Design
To understand this relation, we used evidence development of fibrin sealant as a case study. In general fibrin sealant is a good case study because there is a lot of information available about it.
A systematic review method based on the Cochrane handbook was used to find the evidence development regarding fibrin sealant. We investigated different indications of fibrin sealant, the year of publication, and the phases in clinical trials. To find the procedures and requirements of the approval for fibrin sealant, we searched the government website of their regulatory agencies FDA (Food and Drug Administration), EMA (European Medicine Agency), and CFDA (China Food and Drug Administration).
Results
The relation between evidence development and approval, we found that the cumulative publications of fibrin sealant increased almost in a straight line from 1998 to 2019. Regarding the applications of fibrin sealant, in the first four years after 1998, no new applications were approved, the next four years, two applications were approved, in the four years after that, there were four new applications.
Conclusions
In the first years, the amount of new approved applications is very low, compared to the amount of new publications, but afterwards it goes much faster. Even though fibrin sealant seems to be a Medical Device, the regulatory approval takes time to catch up. For the future research, it would be interesting to also include sales data of fibrin sealant to analyse how sales data influences the medical device companies’ strategies for publication and market approval.
Downloads
References
2. Roger M. Echols. Understanding the regulatory hurdles for antibacterial medical device development in the post-Ketek world. Annals of the New York Academy of Sciences. 2019.p. 153-161.
3. Class 2 Device Recall Viva ICD. [Internet]. US FDA; 2016 Aug 25 [cited 2020 Dec 06]. Available from:
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=148794
4. Cockburn IM. Is the Medical Device Industry in a Productivity Crisis? Innovation Policy and the Economy. MIT Press. 7: (pp. 1 - 32).
5. Data monitor Report. (2019). Germany Medical Device Market Overview – New pricing rules set to negatively impact medical device sales both domestically and internationally. Research Store, Code: HC00002-001; 2007.
6. IMS Health. Pharmerging Shake-up; 2010.
7. PAREXEL White Paper. Medical device innovation, approval, market access, and the "new normal": Emerging FDA review outcome trends for new medical devices; 2010.
8. Adriane Fugh-Berman D M. Off-Label Promotion, On-Target Sales. PLoS Medicine. 2008; 5: 1432-1435.
9. Cinquegrana J, L. D. Legal: Shifting perspective on off-label promotion. Medical device Executive. [Internet]. pharmexec; 2008 [cited 2020 Dec 05]. Available from:
http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=282490.
10. Elliott M. Antman, e. a. A Comparison of Results of Meta-analyses of Randomized Control Trials and Recommendations of Clinical Experts. Treatments for Myocardial Infarction. 1992; 268(2).
11. Andrew D. Oxman G H. The Science of Reviewing Research. Annals of the New York Academy of Sciences. 1993;703: 125–133.
12. Green S, H. J. Chapter 1: Introduction. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration. [Internet]. 2019 Mar [cited 2020 Nov 21]. Available from: www.cochrane-handbok.org
13. Higgins JPT, G. S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 The Cochrane Collaboration [Internet]. 2019 Mar [cited 2020 Nov 21]. Available from:
www.cochrane-handbok.org
14. O’Connor D, G. S. Chapter 5: Defining the review question and developing criteria for including studies. Cochrane Handbook of Systematic Reviews of Interventions. Chichester (UK): John Wiley & Sons; 2008.
15. Lefebvre C, M. Chapter 6: Searching for studies. Cochrane Handbook for Systematic Reviews of Interventions. Wiley; 2008.
16. Higgins JPT, A. D. Chapter 8: Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions. Chichester (UK): John Wiley & Sons, 2008
17. Deeks JJ, H. J. Chapter 9: Analysing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions. Chichester (UK): John Wiley & Sons; 2008.
18. Sterne JAC, E. M. Chapter 10: Addressing reporting biases. Cochrane Handbook for Systematic Reviews of Interventions. Chichester (UK): John Wiley & Sons; 2008.
19. Schunemann HJ, O. A. Chapter 11: Presenting results and ‘Summary of findings’ tables. Cochrane Handbook for Systematic Reviews of Interventions. Chichester (UK): John Wiley & Sons;2008.
20. Schumann HJ, Chapter 12: Interpreting results and drawing conclusions. Cochrane Handbook for Systematic Reviews of Interventions. Chichester (UK): John Wiley & Sons; 2008.
21. Board on Health Care Services. Finding What Works in Health Care: Standards for Systematic Reviews. Institute of Medicine of the National Academies; 2019.
22. Radosevich M, G. H. Fibrin sealant: scientific rationale, production methods, properties and current clinical use. Vox Sang. 1997; 72:133-143.
23. TachoSil, human fibrinogen / human thrombin [Internet]. EMEA; 2016 May 25 [cited 2020 Nov 21]. Available from:
https://www.ema.europa.eu/en/medicines/human/EPAR/tachosil
24. Spotnitz WD, Burks S. Hemostats, sealants, and adhesives: components of the surgical toolbox. Transfusion. 2008;48(7):1502-1516.
25. Bergel, S. Uber Wirkungen des Fibrins. Dtsch Med Wochenschr. 1909; 35:633.
26. Grey, E. Fibrin as a hemostatic in cerebral surgery. Surg Gyn Obstet., 21:452-454, 1915
27. Harvey, S, Fibrin paper as a hemostatic agent. Ann Surg. 1918; 68:66-70.
28. Cronkite EP, L. E, Use of thrombin and fibrinogen in skin grafting. JAMA. 1944;124: 976-978.
29. Matras, H. Fibrin seal: the state of the art. Journal of Oral and Maxillofacial Surgery. 1985; 43(8):605-11.
30. Radosevich M, G.H. Fibrin sealant: scientific rationale, production methods, properties, and current clinical use. Vox Sang. 1997; 72:133-143.
31. Hile, J. Fibrinogen (human): revocation of licenses. Fed Regist. 1978; 43:1131-1132.
32. FDA. Opgehaald van. [Internet]. US FDA; 2012 [cited 2020 Dec 03]. Available from:
http://www.fda.gov/
33. Scheule AM, B. W. Repeated anaphylactic reactions to aprotinin in fibrin sealant. Gastrointest Endo. 1998; 48:83-85.
34. Murthy KK, H. D. Redefining the HIV infectious window period in the chimpanzee model: evidence to suggest that viral nucleic acid testing can prevent blood-borne transmission. Transfusion. 1999; 39:688-693.
35. Butler SP, Current progress in the production of recombinant human fibrinogen in the milk of transgenic animals. Thromb Haemost. 1997;78:537-542.
36. William D. Spotnitz. Fibrin Sealant: Past, Present, and Future: A Brief Review. World J Surg. 2010; 34:632-634.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM
